Briacell Therapeutics Corp. — FY2023 Form 10-K
Reporting period: Fiscal year ended July 31, 2023; U.S. dollars unless otherwise noted. This is an annual report, not a filing for calendar-year Q4. Briacell is a pre-revenue, clinical-stage biotechnology company developing cancer immunotherapies. Its lead candidate, Bria-IMT, is being developed with an immune checkpoint inhibitor for advanced metastatic breast cancer.
Key financial metrics
| Metric | FY2023 | FY2022 |
|---|---|---|
| Revenue | No product revenue reported | No product revenue reported |
| Research and development expense | $15.34 million | $8.02 million |
| General and administrative expense | $7.94 million | $7.27 million |
| Operating loss | $23.27 million | $15.29 million |
| Financial income (expense), net | $2.97 million income | $11.55 million expense |
| Net loss | $20.30 million | $26.84 million |
| Basic and diluted loss per share | $1.30 | $1.73 |
| Net cash used in operating activities | $23.74 million | $12.48 million |
| Cash and cash equivalents at year-end | $21.25 million | $41.04 million |
| Working capital | $25.15 million | $41.41 million |
Operating cash use increased substantially as research and development activity expanded. FY2023 net loss was lower largely because the company recorded a $2.12 million gain from a decrease in the fair value of warrant liabilities; FY2022 included an $11.66 million warrant remeasurement expense. The filing reports no conventional borrowings, but a $29.14 million warrant liability was recorded as a non-current liability. Shareholders’ equity was a deficit of $3.78 million at July 31, 2023, compared with equity of $10.33 million a year earlier.
Changes and business developments
- R&D expense rose approximately 91%, primarily reflecting higher clinical-trial and investigational-drug costs, expanded Bria-IMT work, additional preclinical programs and increased staffing. G&A expense increased approximately 9%.
- Cash declined $19.79 million during FY2023. Financing activities provided $3.95 million, including $4.00 million from issuing 463,408 shares to Prevail Partners at $8.63 per share.
- The company paid InfoWorks an upfront $5.38 million under a clinical-services agreement for the planned pivotal study; $4.70 million remained recorded as prepaid expense at year-end.
- On August 31, 2023, after fiscal year-end, Briacell completed a spinout of certain assets, including Bria-TILsRx and PKC-delta inhibitor programs, into BriaPro. Briacell retained approximately two-thirds ownership; existing Briacell shareholders received BriaPro shares as well as replacement Briacell shares.
Outlook, risks and unusual items
- Management said existing capital resources were expected to cover anticipated liquidity needs for at least 12 months from issuance of the financial statements, while also stating that additional capital would be needed to advance development. It cautioned that financing may not be available on acceptable terms and that operations could need to be curtailed if funding is insufficient.
- The filing describes Bria-IMT’s pivotal Phase 3 study as planned/underway in different passages. The proposed study includes a physician’s-choice comparison, an overall-survival primary endpoint, and planned enrollment of 177 patients in each principal arm, plus 50 in a Bria-IMT regimen arm. Fast Track status does not assure approval.
- Management cited median overall survival of 13.5 months in its advanced metastatic breast cancer study population, versus 6.7–9.8 months in cited literature. These are preliminary, cross-study comparisons; the company’s earlier trials were small and largely single-arm, and results may not predict Phase 3 outcomes.
- Key risks include clinical and regulatory failure, the need for additional financing and potential shareholder dilution, reliance on contract manufacturers and clinical vendors, competition, and the company’s lack of product revenue. Briacell also identified potential BriaPro impairment and execution risks.
- A $230,000 investor dispute settlement was recorded in G&A. The company reported no other material legal proceedings. It also reported that disclosure controls and internal control over financial reporting were effective at July 31, 2023, and that previously identified material-weakness remediation had been completed.
- The financial statements received an unqualified audit opinion. The auditor did not express an opinion on internal control effectiveness.
Important facts for investors to verify
- Current cash, actual operating burn and the timing and terms of any subsequent financing; reconcile management’s stated liquidity horizon with planned trial spending.
- Phase 3 trial status, enrollment progress, protocol and comparator details, interim-analysis criteria, and whether the study is proceeding on the schedule described.
- Whether the reported survival and clinical-benefit signals are confirmed in controlled, adequately powered studies and in the intended patient population.
- The nature and potential dilution of the $29.14 million warrant liability, along with outstanding warrants, options and other equity awards.
- Accounting and financial effects of the BriaPro spinout, including asset transfer, ongoing ownership, services arrangements and any future impairment.